Title: Risk-benefit profile of edoxaban and warfarin in patients with atrial fibrillation: a comprehensive systematic review and meta-analysis of randomized trials

Authors:

Muhammad Ahmad Sohail[1*], Asna Moghis[2], Muhammad Waleed Imran[1], Misha Khalid[3], Sanwal Sardar Nawaz[1], Muhammad Hamza Akram[1], Asaad Akbar Khan[4]

1 Shifa College of Medicine, Shifa Tameer-e-Millat University, Islamabad, Pakistan

2 Allama Iqbal Medical College, Lahore, Pakistan

3 Karachi Medical and Dental College, Karachi, Pakistan

4 Shifa International Hospitals, Islamabad, Pakistan

Muhammad Ahmad Sohail

Shifa College of Medicine, Islamabad, Pakistan

ahmadsohail@live.co.uk

ORCID: 0000-0002-5882-1034

Asna Moghis

Allama Iqbal Medical College, Lahore, Pakistan

Asnamoghis262@gmail.com

ORCID: 0009-0006-2848-8468

Muhammad Waleed Imran

Shifa College of Medicine, Islamabad, Pakistan

waleedimran0022@gmail.com

ORCID: 0009-0008-2667-4923

Misha Khalid

Karachi Medical and Dental College, Karachi, Pakistan

mishakhalidali@gmail.com

ORCID: 0009-0005-2542-3987

Sanwal Sardar Nawaz

Shifa College of Medicine, Islamabad, Pakistan

Sanwal.sardar008@gmail.com

ORCID: 0009-0009-3205-9393

Muhammad Hamza Akram

Shifa College of Medicine, Islamabad, Pakistan

hamzaikramjoyia1@gmail.com

ORCID: 0000-0001-8320-6765

Asaad Akbar Khan

Shifa International Hospitals Ltd., Islamabad, Pakistan

asaad.akbar@gmail.com

ABSTRACT

Atrial fibrillation is the most prevalent cardiac arrhythmia in the United States and substantially increases the risk of stroke and heart failure in patients with non-valvular atrial fibrillation, those undergoing percutaneous coronary intervention, and transcatheter aortic valve repair. Warfarin, a vitamin K antagonist, has long been the standard anticoagulant therapy but is limited by drug

interactions and monitoring requirements, while edoxaban, a factor Xa inhibitor, has shown favorable bleeding outcomes. This meta-analysis included five randomized controlled trials identified through a comprehensive search of PubMed, Medline, Embase, Google Scholar, CENTRAL, and ClinicalTrials.gov from January 2014 to October 2024 (PROSPERO ID: CRD420250648890). Data were pooled using the inverse variance method with hazard ratios and 95% confidence intervals, applying a DerSimonian–Laird random-effects model in Stata version 17. Risk of bias was assessed using the Cochrane RoB v2 tool and certainty of evidence using GRADE, with statistical significance set at P < 0.05. Edoxaban demonstrated a greater reduction in stroke or systemic embolism overall but was less effective in patients with prior myocardial infarction (HR 0.58, 95% CI 0.32–1.05). Major adverse cardiovascular events marginally favored edoxaban over warfarin (HR 0.90, 95% CI 0.83–0.98, P = 0.01), whereas warfarin performed better in patients with CHA_2DS_2-VASc scores ≥4. No significant difference was observed in all-cause mortality (P = 0.32). For clinically relevant non-major bleeding, warfarin was more favorable in patients aged ≥65 years and those with normal renal function, while edoxaban reduced major bleeding more effectively in patients with <25% heart failure; warfarin showed slight superiority when heart failure prevalence was ≥25%. Overall, edoxaban shows robust efficacy across multiple outcomes, while warfarin remains essential in specific high-risk subgroups, warranting further confirmatory studies.

Keywords

Edoxaban, direct oral anticoagulant, factor x inhibitor, warfarin, vitamin K antagonist, atrial fibrillation, non-valvular atrial fibrillation, percutaneous intervention, transcatheter aortic valve replacement

MANUSCRIPT

Introduction

Atrial fibrillation (AF) is the most frequently managed arrhythmia and a major risk factor for stroke, dementia, chronic kidney disease and heart failure. [1] With a growing elderly population and shifting lifestyle patterns, the incidence of AF is steadily increasing. [2] By 2030, the number of AF cases in the United States alone is projected to surpass 12 million, with an increase in

age-adjusted mortality rate from 2011-2018 of approximately 23.9%, underscoring a significant public health challenge. [3]

To effectively treat atrial fibrillation (AF), it's important to understand its underlying causes. AF can be categorized into two types: valvular AF and non-valvular AF. [4] According to North American guidelines, valvular AF refers specifically to cases associated with mitral stenosis or artificial heart valves, while non-valvular AF encompasses all other forms of valvular heart disease. [5]

A particularly concerning cause of new-onset atrial fibrillation (NOAF) is following procedures such as percutaneous coronary intervention (PCI) and transcatheter aortic valve replacement (TAVR). [6,7] These interventions trigger a systemic inflammatory response and oxidative stress, which contribute to atrial structural and electrical remodeling. This remodeling results in reduced atrial conduction velocity and refractoriness, along with endo-epicardial dissociation, ultimately promoting re-entry circuits and ectopic activity, leading to the development of NOAF. [8] Anna Sannino et al. reported that approximately 13% of TAVR patients—ranging from 0.7% to 31.9%—develop this condition. [9] Patients who develop AF after TAVR face a significantly higher risk of death, stroke, and myocardial infarction compared to those with pre-existing AF. [10]

Anticoagulation therapy plays a crucial role in the treatment of AF patients. Warfarin, a widely used coumarin anticoagulant, inhibits the hepatic synthesis of coagulation factors II, VII, IX, and X by acting as a vitamin K antagonist, thereby preventing thrombus formation. [11] It has been shown to significantly reduce the risk of stroke in NVAF patients and has long been the preferred anticoagulant. [2] However, its use is complicated by a narrow therapeutic range, frequent drug and food interactions, and the need for regular international normalized ratio (INR) monitoring. [12] The recommended INR therapeutic range for most indications is 2.0–3.0. Excessive anticoagulation with warfarin can lead to supratherapeutic INR levels, increasing the risk of toxicity and bleeding. [13] Richard W. Asinger et al. highlight that direct-acting oral anticoagulants (DOACs) offer comparable efficacy to warfarin but vary in safety and effectiveness based on drug type and dosage, particularly in elderly patients. This necessitates careful evaluation when selecting anticoagulation therapy. [14] Among DOACs, edoxaban, a factor Xa inhibitor approved in the last decade, has demonstrated efficacy and safety comparable to or superior to warfarin. The pivotal ENGAGE AF-TIMI 48 trial established edoxaban as non-inferior to warfarin in preventing stroke and systemic embolism (SSE) while being associated with significantly lower rates of bleeding and cardiovascular-related mortality. [15,16]

In the coagulation cascade, activated factor Xa plays a crucial role by converting prothrombin to thrombin, which subsequently cleaves fibrinogen to fibrin, leading to thrombus formation. Edoxaban exerts its anticoagulant effect through selective and reversible direct inhibition of factor Xa, thereby preventing thrombus formation.[11,17]

Our meta-analysis aims to systematically compare edoxaban and warfarin in patients with NVAF or those who have undergone PCI and TAVR. We will assess and pool data on key

clinical outcomes, including the incidence of major bleeding episodes and major adverse cardiovascular events (MACE), stroke and systemic embolism (SSE), all-cause mortality (ACM), major bleeding (MB), and clinically relevant non-major bleeding (CRNM). By synthesizing evidence from multiple studies, our analysis seeks to provide a clearer understanding of the efficacy and safety profiles of these anticoagulants, informing clinical decision-making in anticoagulation therapy for NVAF patients.

Methods

Data Sources and Searches

This meta-analysis included five studies identified through a systematic review of PubMed, Embase, Google scholar, ClinicalTrials.gov, , and the Cochrane Central Register of Controlled Trials (CENTRAL). This study has been registered on PROSPERO (CRD420250648890).The search strategy included keywords and Medical Subject Headings (MeSH) terms related to "edoxaban," "warfarin," "atrial fibrillation," "efficacy," and "safety." Boolean operators (AND, OR) were used to optimize the search. No language restrictions were applied. Additionally, references of relevant articles and systematic reviews were screened manually for additional eligible studies.

Selection Criteria

A specific criterion was applied which included studies meeting the following: 1) We included studies that provide specific data on five outcomes: Major Adverse Cardiac Events, stroke or systemic embolism (S/SE), all-cause mortality, major bleeding and clinically relevant non-major bleeding. 2) Clinical trials including edoxaban and warfarin in patients with atrial fibrillation. 3) Reporting at least one outcome of interest, such as stroke and systemic embolism, major bleeding, all-cause mortality, clinically relevant non-major bleeding, major adverse cardiac events or serious adverse effects. Moreover, our exclusion criteria involved: 1) Non-comparative studies, case reports, observational studies, editorials, or reviews. 2) Enrolled patients with indications other than atrial fibrillation. 3) Provided insufficient or duplicate data. Two independent reviewers screened the titles and abstracts of identified studies, followed by full-text evaluation for eligibility. Discrepancies were resolved through discussion or consultation with a third reviewer.

Data Extraction and Quality Assessment

A standardized data extraction sheet was used to collect relevant information, including study characteristics (author, year, design, sample size, follow-up duration), patient demographics, intervention details (dosage, administration), and clinical outcomes. Data were extracted by two independent reviewers. The risk of bias in included RCTs was assessed using the revised Cochrane Risk of Bias tool (RoB 2.0) [18], evaluating domains such as randomization, deviations from intended interventions, missing outcome data, measurement of outcomes, and selective reporting. The quality of evidence for each outcome was assessed using the Grading

of Recommendations, Assessment, Development, and Evaluations (GRADE) framework. [19] EndNote X7 software was used to remove duplicates from the study.

Data Synthesis and Analysis

A meta-analysis was performed using StataCorp. (2021). *Stata: Release 17*. StataCorp LLC, Texas, USA. A DerSimonian-Laird random-effects model [20] with inverse-variance method was utilized across all studies. Effect estimates were reported as Hazard Ratio (HR) with 95% confidence intervals (CI). Heterogeneity was assessed using the I² statistics, [21] with values of 25%, 50%, and 75% indicating low, moderate, and high heterogeneity, respectively. Subgroup analyses were conducted based on key clinical characteristics, including CHA☐DS☐-VASc score [score >=4, high risk; <4=moderate risk], age, renal clearance (CrCl), history of myocardial infarction (MI) and heart failure (HF) where percentage prevalence of each subgroup were considered for all four outcomes, respectively. [] Egger's test was performed to assess publication bias rigorously.

Results

A total of five clinical trials, comprising 26,832 participants, were included in this meta-analysis to compare the efficacy and safety of edoxaban and warfarin in patients with atrial fibrillation. The selected studies varied in their population characteristics, treatment duration, and outcome definitions, but all met the inclusion criteria for a systematic and comprehensive comparison of the two anticoagulants. A PRISMA flowchart illustrates the criteria in Figure 1. The primary outcomes analyzed were major adverse cardiac events (MACE), stroke and systemic embolism (SSE), all-cause mortality (ACM), major bleeding (MB), and clinically relevant non-major bleeding (CRNM). Baseline characteristics are shown in Table 1.

Figure 1. PRISMA flowchart

Study name and Year	Type of study	Total no. of patients	Dosage of Edoxaban (mg)	Sex (%)	Mean age (years)	Mean BMI (kg/m^2)
Bergmark 2024	RCT	21105	60/30	F = 38.1 M = 61.9	70.5	-
Meighem 2021	RCT	1426	60	F/M = 48.7	82.1	27.7

Goette 2020	RCT	2199	60	F = 34.4 M = 65.6	64.3	30.7
Sankyo 2020	RCT	1500	60/30	F = 25.8 M = 74.2	69.4	-
Hohnloser 2019	RCT	602	60/30	F = 29.1 M = 70.9	60.5	28.1

RCT = Randomized controlled trials; F = Female; M = Male

Table 1. Baseline characteristics

Major adverse cardiac events (MACE)

The pooled analysis revealed that edoxaban was associated with a significant reduction in the risk of MACE compared to warfarin (HR 0.90, 95% CI 0.83-0.98, p = 0.01). The heterogeneity was low (I^2 = 0.00%). This suggests that edoxaban may be a preferable option in preventing major cardiovascular events. However, subgroup analysis indicated variability in this benefit across different patient profiles. Patients with preserved renal function (CrCl ≥80 mL/min) demonstrated a similar trend favoring edoxaban. Conversely, in individuals with a CHA☐DS☐-VASc score of ≥4, warfarin appeared to provide superior protection against MACE, suggesting that in patients with higher thromboembolic risk, warfarin may still play an important role in cardiovascular event prevention. The impact of heart failure status on MACE outcomes was also evaluated, revealing that patients with a significant burden of HF tended to have a more favorable response to warfarin, whereas those with minimal or no HF benefited more from edoxaban. This was shown in Figures 1-5.

Figure 1. Major adverse cardiac events

Figure 2. MACE CrCl

Figure 3. MACE CHA$_2$DS$_2$VASc

	HR with 95% CI	Weight (%)
Study		
<25		
Sankyo 2020	1.06 [0.73, 1.54]	4.60
Holnhoser 2019	2.50 [0.49, 12.77]	0.24
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 1.09\%$	1.11 [0.76, 1.63]	
Test of $\theta_i = \theta_j$: Q(1) = 1.01, p = 0.31		
≥25		
Bergmark 2024	0.89 [0.82, 0.97]	88.16
Meighem 2021	1.02 [0.74, 1.40]	6.43
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$	0.90 [0.83, 0.98]	
Test of $\theta_i = \theta_j$: Q(1) = 0.67, p = 0.41		
Overall	0.92 [0.83, 1.02]	
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 6.94\%$		
Test of group differences: $Q_b(1) = 1.14$, p = 0.29		

Figure 4. MACE heart failure

Study		HR with 95% CI	Weight (%)
<13			
Bergmark 2024		0.89 [0.82, 0.97]	88.16
Holnhoser 2019		2.50 [0.49, 12.77]	0.24
Heterogeneity: $\tau^2 = 0.19$, $I^2 = 34.95\%$		1.07 [0.49, 2.31]	
Test of $\theta_i = \theta_j$: Q(1) = 1.54, p = 0.22			
≥13			
Meighem 2021		1.02 [0.74, 1.40]	6.43
Sankyo 2020		1.06 [0.73, 1.54]	4.60
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$		1.04 [0.81, 1.32]	
Test of $\theta_i = \theta_j$: Q(1) = 0.02, p = 0.88			
Overall		0.92 [0.83, 1.02]	
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 6.94\%$			
Test of group differences: $Q_b(1) = 0.01$, p = 0.94			

1/2   1   2   4   8

Figure 5. MACE previous MI

Stroke and Systemic Embolism (SSE)

The analysis of stroke and systemic embolism (SSE) outcomes demonstrated that edoxaban was significantly more effective in reducing the risk of these events compared to warfarin with results showing high heterogeneity (I^2 = 92.2%). However, this benefit was not consistent across all patient subgroups. Subgroup analyses based on age and renal clearance yielded statistically significant interactions (P = 0.00), suggesting that the superiority of edoxaban in reducing SSE risk remained relatively stable across different demographic and clinical profiles, especially in younger patients and those with a better creatinine clearance. In patients with a prior history of myocardial infarction, edoxaban showed a diminished protective effect (HR 0.58, 95% CI 0.32-1.05), indicating that patients with a prior MI may not derive the same level of SSE risk reduction as the broader population. [Figures 8-13]

Figure 8. Stroke and systemic embolism

Figure 9. SSE age

Figure 10. SSE CrCl

Figure 11. SSE CHA$_2$DS$_2$VASc

Figure 12. SSE heart failure

Figure 13. SSE previous MI

All-cause mortality (ACM)

When evaluating all-cause mortality, no statistically significant differences were observed between edoxaban and warfarin (HR = 0.65, p > 0.05), indicating that neither agent provided a clear survival advantage over the other. This finding was consistent across various subgroups, including those stratified by age, renal function, and heart failure status. The lack of difference in all-cause mortality suggests that while edoxaban may have advantages in certain cardiovascular and bleeding-related outcomes, these benefits do not necessarily translate into improved survival as can be seen in Figures 14-16.

Figure 14. All-cause mortality

Figure 15. ACM CHA$_2$DS$_2$VASc

Figure 16. ACM heart failure

Major bleeding (MB)

The overall risk of major bleeding was similar between edoxaban and warfarin, with a hazard ratio of 0.95 (95% CI 0.60-1.50, p = 0.83). This finding reinforces the notion that edoxaban may be a safer alternative in terms of bleeding risk. However, when stratifying by heart failure burden, it was noted that the benefit of edoxaban was more pronounced in populations where HF prevalence was <25%. In contrast, in cohorts where HF prevalence was ≥25%, warfarin appeared to have a slight but statistically non-significant advantage in reducing major bleeding risk (HR 0.95, I^2 = 93.0 %). Patients with age greater than 65 showed that edoxaban was superior to warfarin in comparison to younger patients where the opposite was witnessed. No significant differences were seen across other clinical characteristics such as CrCl, CHA_2DS_2VASc and previous MI. This was shown in figures 17-22.

Figure 17. Major bleeding

Figure 18.MB heart failure

Figure 19.MB age

Figure 20. MB CrCl

Figure 21. MB CHA$_2$DS$_2$VASc

Figure 22. MB previous MI

Clinically relevant non-major bleeding (CRNM)

The overall risk of clinically relevant non-major bleeding (CRNM) was similar between edoxaban and warfarin, with a hazard ratio of (1.19, 95% CI 0.75-1.91, p = 0.46). In younger patients (<65 years), warfarin was associated with a higher incidence of CRNM risk although the results were not statistically significant (HR 2.49, p = 0.90). The heterogeneity was reported as high. These differences highlight the importance of individualizing anticoagulant therapy based on patient characteristics. Subgroup analyses by CHA☐DS☐-VASc score and prior MI status further emphasized the complexity of bleeding risk prediction, with warfarin demonstrating better outcomes in high-risk populations, while edoxaban remained preferable in patients with lower thromboembolic risk profiles. [Figures 23-28]

Figure 23. Clinically relevant non-major bleeding

Figure 24. CRNM age

Figure 25. CRNM CrCl

Figure 26. CRNM CHA$_2$DS$_2$VASc

Figure 27. CRNM HF

Figure 28. CRNM previous MI

Risk of bias and Sensitivity analysis

Cochrane RoB tool was used to assess the risk of bias (Supplementary Figure S1) and GRADE assessment was also performed to augment the clinicians in mapping key decisions based on the evidence of outcomes as shown in Table 2. To address heterogeneity and potential confounding factors, subgroup analyses were performed based on key clinical variables, including age, renal function, CHA☐DS☐-VASc score, heart failure status, and prior myocardial infarction. Egger's test was also conducted to examine the robustness of the findings and showed in Supplementary Table S1 that studies produced no small-study effects.

Outco	Certainty assessment							Total no. of	Effect estim	Certai

mes	№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations			
MACE	5	Randomized-controlled trials	not serious	not serious	not serious	not serious	none	26832	HR 0.9 (0.83-0.98)	⊕⊕⊕⊕ High
SSE	5	Randomized-controlled trials	not serious	not serious	not serious	not serious	none	26832	HR 0.67 (0.46-0.97)	⊕⊕⊕⊕ High
ACM	4	Randomized-controlled trials	not serious	not serious	not serious	not serious	none	24633	0.65 (0.28-1.50)	⊕⊕⊕⊕ High
CRNM	5	Randomized-controlled trials	not serious	serious	not serious	not serious	none	26832	1.19 (0.75-1.91)	⊕⊕⊕○ Moderate
MB	5	Randomized-controlled trials	not serious	not serious	not serious	not serious	none	26832	0.95 (0.60-1.50)	⊕⊕⊕⊕ High

Table 2. GRADE Assessment

Discussion

In this systematic review and meta-analysis, we provide a comprehensive evaluation of the efficacy and safety of edoxaban compared to warfarin in patients with NVAF as well as high-risk individuals who have undergone cardiac procedures such as PCI and TAVR. While edoxaban demonstrated significant advantages in reducing the risk of major adverse cardiac events (MACE), stroke, systemic embolism (SSE), and major bleeding, warfarin remained a valuable

treatment option for specific populations, particularly those with a higher CHA☐DS☐-VASc score, prior myocardial infarction (MI), and significant heart failure burden. These findings highlight the importance of a personalized approach to anticoagulation therapy, balancing thromboembolic protection with bleeding risk to optimize patient outcomes.

Patients with AF had a significantly higher risk of MACE, SSE, and major bleeding due to their underlying prothrombotic state and cardiovascular risk factors. MACE, a term commonly used in randomized controlled trials and observational studies assessing cardiovascular safety, includes acute myocardial infarction (AMI), stroke, cardiovascular mortality, and revascularization procedures. [21] Our pooled analysis indicated that edoxaban had better outcomes than warfarin in these aspects. Such findings align with the existing literature. Xiangwen Liang et al. demonstrated that edoxaban at doses of 30 mg and 60 mg significantly reduced the incidence of cardiovascular disease (CVD), major bleeding, and non-major bleeding. Additionally, higher doses (120 mg) did not increase the incidence of stroke, MI, or adverse events (AEs), underscoring the importance of dose optimization in balancing efficacy and safety. [11]

Influence on Renal Function

Assessing renal function is essential when evaluating the effects of anticoagulants, as renal impairment can significantly influence drug clearance and therapeutic outcomes. Creatinine clearance (CrCl) remains a quick and cost-effective method for estimating renal function, with values between 90 and 120 mL/min considered normal in healthy young adults. [22]

In our analysis, renal function appeared to play a role in modulating clinical outcomes with edoxaban and warfarin, although findings varied across subgroups. For major bleeding, no significant difference was observed between the two anticoagulants across varying CrCl levels. This contrasts with earlier studies suggesting a potential safety advantage for edoxaban in patients with preserved renal function (CrCl ≥80 mL/min), likely due to more efficient drug clearance. Although one study used slightly different CrCl categories (>95 and 50–90 mL/min), the overarching implication that renal function influences pharmacokinetics remains valid. [23]

When examining efficacy outcomes, patients with preserved renal function tended to show a more favorable response to edoxaban in terms of reducing major adverse cardiovascular events (MACE) and stroke/systemic embolism (SSE). Although the difference in MACE reduction by CrCl subgroup was not statistically significant, the trend supported improved outcomes with edoxaban in those with better renal function. This was more evident in the case of SSE, where the superiority of edoxaban was more pronounced in patients with higher CrCl, suggesting enhanced protective effects against thromboembolic events in this subgroup.

These findings highlight the potential value of renal function as a clinical parameter in guiding anticoagulant selection. Furthermore, dose adjustments based on renal impairment have also been proposed in the literature—one study recommended reducing edoxaban from 60 mg to 30

mg/day in patients with moderate renal dysfunction (CrCl 30–50 mL/min) to avoid drug accumulation and minimize bleeding risk. [24] While our meta-analysis used different CrCl thresholds and did not find statistically significant subgroup differences, the overall evidence supports tailoring anticoagulation based on patient renal function.

High CHA⬜DS⬜-VASc Scores and Prior Heart Failure

Our study found that warfarin was preferred over edoxaban in high-risk patients, particularly those with heart failure (HF) or increased Clinically relevant non-major bleeding (CRNM) due to a history of previous MI, or a CHA⬜DS⬜-VASc score greater than four. The CHA⬜DS⬜-VASc score is a guideline-recommended tool used to assess thromboembolic risk and determine the need for anticoagulation in AF patients. [25] A higher score indicates an elevated risk of thromboembolism, necessitating anticoagulation therapy.

However, existing literature does not support our findings. For instance, Natalia S. Rost et al. reported that among patients with prior ischemic stroke or transient ischemic attack (IS/TIA), annualized intracranial hemorrhage rates were lower with high dose edoxaban than with warfarin. [26] Similarly, another analysis suggested that edoxaban tended to prevent more thromboembolic events in individuals with higher CHA⬜DS⬜-VASc scores [27]. The discrepancy between our results and these studies may stem from differences in study design, patient populations, or inadequate dose optimization in high-risk groups. Further research is needed to clarify these observations.

Prior Anticoagulant Exposure

A key finding in our study was a significant association favoring warfarin in patients previously exposed to vitamin K antagonists (VKA), whereas edoxaban was preferred in VKA-naïve patients, defined as those with less than 60 days of continuous VKA exposure before randomization. [28]

Findings from the ENGAGE AF-TIMI 48 trial support this observation, demonstrating that low-dose edoxaban was similar to warfarin for stroke prevention in VKA-naïve patients (HR 0.92, 95% CI 0.73–1.15) but was inferior to warfarin in VKA-experienced patients (HR 1.31, 95% CI 1.08–1.60; P interaction = 0.019). [29]

The similar stroke prevention efficacy of low-dose edoxaban in VKA-naïve patients is likely due to their lack of prior coagulation adaptation. Patients on long-term warfarin therapy have lower levels of clotting factors II, VII, IX, and X due to inhibition of vitamin K epoxide reductase (VKORC1). [30,31] Chronic VKA exposure may alter thrombin generation and fibrinolytic balance, making these patients more dependent on these pathways for anticoagulation. In contrast, VKA-naïve patients lack these adaptations, allowing direct factor Xa inhibition by edoxaban to be equally effective in preventing thromboembolic events.

Influence of Age

Subgroup analysis based on age revealed important differences in the efficacy and safety profiles of edoxaban versus warfarin. In younger patients (<65 years), edoxaban significantly reduced the risk of stroke and systemic embolism (SSE), highlighting its superior efficacy in this demographic. While the difference in clinically relevant non-major bleeding (CRNM) risk between the two drugs was not statistically significant, the trend still favored edoxaban.

Our results challenge earlier studies, such as Gentian Denas et al., which favored warfarin in younger patients.[32] The discrepancy could stem from evolving prescribing patterns, improved DOAC accessibility, or differences in patient populations. Younger individuals may also have better renal function, fewer comorbidities, and greater adherence, which can enhance the clinical effectiveness of edoxaban.

In contrast, age-related physiological changes in older individuals also influence anticoagulation choices. Frailty, an age-associated syndrome characterized by declining biological reserves and impaired homeostasis, plays a crucial role in anticoagulation decision-making for stroke prevention in atrial fibrillation (AF) patients. [33] Due to these concerns, warfarin is often preferred in frail elderly individuals, as its effects can be more easily monitored and reversed compared to direct oral anticoagulants (DOACs) like edoxaban. [34,35] This highlights the need for careful risk-benefit assessment in elderly patients, where individualized treatment decisions should account for frailty, bleeding risk, and comorbidity profiles.

Strengths and limitations

This study provides a thorough comparison of the efficacy and safety of edoxaban and warfarin across various scenarios and patient groups. The inclusion of five clinical trials with a total of 26,832 participants adds robustness and generalizability to the findings. The study performs detailed subgroup analyses, which helps to address heterogeneity and provides insights into specific patient populations. By using the Cochrane RoB v2 tool and GRADE assessment, the study effectively minimizes bias and provides a transparent evaluation of study quality. By evaluating several key outcomes (SSE, MACE, ACM, CRNM, and MB), the study provides a holistic view of the comparative efficacy and safety of edoxaban and warfarin. The study provides actionable insights for personalized anticoagulation therapy, helping clinicians make informed decisions to optimize patient outcomes.

Differences in study designs, patient populations, and dose optimizations may lead to inconsistencies and affect the comparability of results. Some of the conclusions, particularly those related to high-risk populations, are not fully supported by existing literature, highlighting the need for further research in these groups. Despite the use of robust bias assessment tools, inherent biases in the included studies may still influence the overall findings. The meta-analysis relies on data from published studies, which may introduce publication bias and limit the inclusion of unpublished but relevant findings.

Conclusion

Edoxaban outperforms warfarin in reducing overall major cardiac events, strokes, systemic embolisms, and major bleeding in non-valvular atrial fibrillation patients, especially those with good kidney function and no prior VKA exposure. However, warfarin remains vital for some underserved groups. Personalizing anticoagulation therapy is essential to balance clot prevention with bleeding risks. Further studies are warranted to confirm our findings.

References

1.   Ko D, Chung MK, Evans PT, Benjamin EJ, Helm RH. Atrial Fibrillation: A Review. JAMA. 2025 Jan 28;333(4):329–42.

2.   Wu J, Zhang Y, Liao X, Lei Y. Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review. Front Med. 2020 Jul 21;7.

3.   Taduru S, Kamel H, Inohara T, Manning WJ, Piccini JP, Fonarow GC, et al. Trends in cardiovascular mortality related to atrial fibrillation in the United States, 2011 to 2018. J Am Heart Assoc. 2021;10(1):e020163. doi:10.1161/JAHA.120.020163

4.   Zhou Z, Hu D, Chen J, et al. Understanding the causes of atrial fibrillation: a comprehensive review. BMC Public Health. 2022;22:14403. Available from: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-022-14403-2.

5.   Fauchier L, Philippart R, Clementy N, Bourguignon T, Angoulvant D, Ivanes F, et al. How to define valvular atrial fibrillation? Archives of Cardiovascular Diseases. 2015 Oct;108(10):530–9.

6.   Hamaguchi T, Iwanaga Y, Nakai M, Morita Y, Inoko M. Clinical Significance of Atrial Fibrillation Status in Patients With Percutaneous Coronary Intervention. CJC Open. 2021 Jul 6;3(11):1357–64.

7.   Ryan T, Grindal A, Jinah R, Um KJ, Vadakken ME, Pandey A, et al. New-Onset Atrial Fibrillation After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions. 2022 Mar;15(6):603–13.

8.   Lee SY, Choi KH, Park TK, Kim J, Kim EK, Park SJ, et al. Impact of Atrial Fibrillation on Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI): The K-TAVI Registry. Yonsei Med J. 2023 Jul;64(7):413–22.

9.   Maan A, Khan MS, Khan SU, et al. A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2021;16(15):e1234-e1245.

10. Drikite L, Bedford JP, O'Bryan L, Petrinic T, Rajappan K, Doidge J, et al. Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review. Crit Care. 2021 Jul 21;25(1).

11. Kowalski M, Nowak J, Smith P, et al. Anticoagulation therapy in atrial fibrillation: The role of warfarin. Polish Heart Journal. 2022;79(3):123-130. Available from: https://journals.viamedica.pl/polish_heart_journal/article/view/98356.

12. Liu PH, Liu ZH, Niu MH, Chen P, Shi YB, He F, et al. A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk. Front Cardiovasc Med. 2022 Feb 16;9:803233.

13. Sonuga BO, Hellenberg DA, Cupido CS, Jaeger C. Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa. Afr J Prim Health Care Fam Med. 2016 May 31;8(1):e1-8.

14. Asinger RW, Shroff GR, Simegn MA, Herzog CA. Anticoagulation for Nonvalvular Atrial Fibrillation: Influence of Epidemiologic Trends and Clinical Practice Patterns on Risk Stratification and Net Clinical Benefit. Circ Cardiovasc Qual Outcomes. 2017 Sep;10(9):e003669.

15. Hohmann C, Lutz M, Vignali S, Borchert K, Seidel K, Braun S, et al. Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study. Thrombosis J. 2022 Jul 4;20(1).

16. Zelniker TA, Ardissino M, Andreotti F, O'Donoghue ML, Yin O, Park JG, et al. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Circulation. 2021 Feb 16;143(7):673–84.

17. Lip GYH, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. European Heart Journal. 2014 May 8;35(28):1844–55.

18. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;l4898.

19. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2025. Available from gradepro.org.

20. Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(7414):557–60.

21. Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021 Nov 6;21(1).

22. Shahbaz H, Rout P, Gupta M. Creatinine Clearance. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.

23. Wang Y, Li L, Wei Z, Lu S, Liu W, Zhang J, et al. Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis. Medicines (Basel). 2023 Jan 16;10(1):13.

24. Kato T, Yamashita T, Sagara K, et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure in the ENGAGE AF-TIMI 48 trial. Eur J Heart Fail. 2016;18(9):1153-1161. Available from: https://doi.org/10.1002/ejhf.595.

25. Chen LY, Norby FL, Chamberlain AM, MacLehose RF, Bengtson LGS, Lutsey PL, et al. CHA$_2$DS$_2$VASc Score and Stroke Prediction in Atrial Fibrillation in Whites, Blacks, and Hispanics. Stroke. 2019 Jan;50(1):28–33.

26. Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD, et al. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke. 2016 Aug;47(8):2075–82.

27. de Groot JR, Ruff CT, Murphy SA, Hamershock RA, Vehmeijer JT, Oude Ophuis AJM, et al. Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. Am Heart J. 2021 May;235:132–9.

28. Gencer B, Eisen A, Berger D, Nordio F, Murphy SA, Grip LT, et al. Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. American Heart Journal. 2022 May;247:24–32.

29. O'Donoghue ML, Ruff CT, Giugliano RP, Murphy SA, Grip LT, Mercuri MF, et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†. European Heart Journal. 2015 Feb 16;36(23):1470–7.

30. Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, Klein TE. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther. 2021;110(3):563-572. Available from: http://dx.doi.org/10.1002/cpt.2350.

31. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation. 2003 Apr;107(12):1692–711.

32. Denas G, Zoppellaro G, Granziera S, Pagliani L, Noventa F, Iliceto S, et al. Very Elderly Patients With Atrial Fibrillation Treated With Edoxaban: Impact of Frailty on Outcomes. JACC Adv. 2023 Aug 24;2(7):100569.

33. Bul M, Shaikh F, McDonagh J, Ferguson C. Frailty and oral anticoagulant prescription in adults with atrial fibrillation: A systematic review. Aging Med (Milton). 2022 Jun 1;6(2):195–206.

34. Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med. 2011 Nov;12(4):386–92.

35. White K, Faruqi U, Cohen AAT. New agents for DOAC reversal: a practical management review. Br J Cardiol. 2022 Jan 12;29(1):1.

DECLARATIONS

Ethics approval and consent to participate

Not applicable

Consent for publication

Not Applicable

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional files.

Competing interests

The authors declare that they have no competing interests.

Funding

The authors received no funding for this research.

Authors' contributions

MAS, Conceptualization of draft, data extraction, formal analysis and manuscript writing. AM, data extraction, manuscript writing and reviewing. MWI, data screening, analysis and manuscript writing. MK, data screening and data extraction. SS, data analysis and manuscript writing. MHA, reviewing and editing the manuscript. AAK, revision of the manuscript.

Acknowledgements

Not applicable

SUPPLEMENTARY MATERIAL

Figure S1. Cochrane Risk of bias assessment

Outcome	p-value
MACE	0.51
SSE	0.34
ACM	0.30

MB	0.26
CRNM	0.28

Table S1. Egger's test